{
  "_metadata": {
    "version": "2.0",
    "extracted_from": "Kymera Therapeutics Corporate Presentation January 2026",
    "extraction_date": "2026-02-04",
    "analyst_reviewed": true
  },

  "ticker": "KYMR",
  "name": "Kymera Therapeutics",

  "company": {
    "name": "Kymera Therapeutics",
    "ticker": "KYMR",
    "exchange": "NASDAQ",
    "headquarters": "Watertown, MA",
    "website": "https://www.kymeratx.com",
    "ir_contact": "investors@kymeratx.com",
    
    "one_liner": "Industry leader in developing oral degrader medicines - revolutionizing immunology with oral drugs that have biologics-like activity",
    
    "company_description": "Kymera is pioneering targeted protein degradation (TPD) to develop oral small molecule drugs that can achieve biologics-like efficacy. The company focuses on historically undruggable targets (transcription factors, scaffolding kinases) in immunology and inflammation, with a pipeline of first-in-class degraders targeting STAT6, IRF5, and IRAK4."
  },

  "investment_thesis_summary": {
    "core_thesis": "Kymera is the first company to clinically demonstrate that oral protein degraders can match injectable biologic efficacy in immunology, potentially transforming treatment paradigms for >140M patients with Type 2 inflammation and autoimmune diseases.",
    
    "key_value_drivers": [
      "KT-621 (STAT6): Phase 1b data matches Dupixent - 'Dupilumab-in-a-pill' potential",
      "KT-579 (IRF5): Best-in-class preclinical with 100% survival in lupus models",
      "Platform validation: Multiple targets (STAT6, IRF5, IRAK4) showing consistent translation",
      "Strategic partnerships: Sanofi (IRAK4) and Gilead (CDK2) validate platform",
      "Large markets: >$100B combined TAM in immunology"
    ]
  },

  "platform": {
    "name": "Targeted Protein Degradation (TPD)",
    "description": "Kymera's platform uses heterobifunctional degraders (PROTACs) and molecular glues to eliminate disease-causing proteins rather than just inhibiting them.",
    
    "unique_capabilities": [
      {
        "capability": "Target Selection",
        "description": "Pursuing historically undrugged targets (transcription factors, scaffolding proteins) in highly validated pathways"
      },
      {
        "capability": "Chemistry",
        "description": "Finding ligands to historically undrugged targets; designing degraders with absolute selectivity"
      },
      {
        "capability": "Translation",
        "description": "Deep expertise in target-drug interplay to optimize degradation across tissues and cell types"
      },
      {
        "capability": "Development",
        "description": "Leverage learnings from early studies (new biomarkers, endpoints) to derisk mid/late-stage development"
      }
    ],
    
    "degrader_advantage": {
      "vs_inhibitors": {
        "mechanism": "Inhibitors block ~80% of target; degraders eliminate >95%",
        "kinetics": "Inhibitors require continuous exposure; degraders work catalytically with transient exposure",
        "targets": "Inhibitors need enzymatic pockets; degraders work on any protein with a binder"
      },
      "vs_biologics": {
        "administration": "Degraders are oral; biologics are injectable",
        "manufacturing": "Small molecules are cheaper to manufacture; no cold chain needed",
        "immunogenicity": "No anti-drug antibodies with small molecules"
      }
    },
    "source": {"id": "kymr_corporate_2026", "slide": "4, 7", "verified": false}
  },

  "pipeline_summary": {
    "total_programs": 4,
    "clinical_stage": 3,
    "partnered": 2,
    "wholly_owned": 2,
    
    "programs": [
      {
        "asset": "KT-621",
        "target": "STAT6",
        "stage": "Phase 2b",
        "ownership": "Wholly-owned",
        "indications": "AD, Asthma, COPD, EoE, CRSwNP, CSU, PN, BP",
        "next_catalyst": "BROADEN2 Phase 2b AD data - Mid-2027",
        "market_opportunity": ">$20B"
      },
      {
        "asset": "KT-579",
        "target": "IRF5",
        "stage": "Phase 1 starting Q1 2026",
        "ownership": "Wholly-owned",
        "indications": "SLE, SjÃ¶gren's, RA, IBD, SSc, DM",
        "next_catalyst": "Phase 1 HV data - 2H 2026",
        "market_opportunity": ">$45B"
      },
      {
        "asset": "KT-485",
        "target": "IRAK4",
        "stage": "Phase 1 expected 2026",
        "ownership": "Partnered (Sanofi)",
        "indications": "HS, AD, Asthma, COPD, RA, SLE, IBD",
        "next_catalyst": "Phase 1 start - 2026",
        "market_opportunity": ">$55B"
      },
      {
        "asset": "CDK2 Molecular Glue",
        "target": "CDK2",
        "stage": "Preclinical",
        "ownership": "Partnered (Gilead)",
        "indications": "Breast cancer, solid tumors",
        "next_catalyst": "IND filing",
        "market_opportunity": "~$18B (CDK4/6i market)"
      }
    ],
    "source": {"id": "kymr_corporate_2026", "slide": 11, "verified": false}
  },

  "financials": {
    "note": "Specific financials not provided in presentation - refer to SEC filings",
    "cash_runway": "Into 2029 (per presentation)",
    "partnerships_value": {
      "sanofi_irak4": {
        "upfront": "$150M received",
        "milestones": "Up to $2B",
        "royalties": "Tiered double-digit"
      },
      "gilead_cdk2": {
        "upfront": "$85M",
        "milestones": "Up to $750M"
      }
    }
  },

  "market_opportunity": {
    "total_immunology_patients": "~160M diagnosed",
    "on_advanced_therapies": "~5M (3%)",
    "on_non_advanced_therapies": "~90M (58%)",
    "untreated": "~62M (39%)",
    "advanced_therapy_market": ">$100B annual sales",
    "key_insight": "Vast majority of patients do not have access to advanced systemic therapies - oral degraders could dramatically expand access",
    "source": {"id": "kymr_corporate_2026", "slide": 5, "verified": false}
  },

  "competitive_positioning": {
    "moat": [
      "First-mover in oral immunology degraders",
      "Clinical proof-of-concept with KT-621",
      "Platform validated across multiple targets",
      "Deep expertise in transcription factor degradation",
      "Strong IP portfolio"
    ],
    "differentiation": [
      "Only company with clinical STAT6 degrader",
      "Only company with clinical IRF5 program",
      "Oral drugs vs injectable biologics",
      "Degraders vs inhibitors for undruggable targets"
    ]
  },

  "management": {
    "note": "Specific management details not provided in presentation",
    "ceo": {
      "name": "Nello Mainolfi, PhD",
      "background": "Founder; former Novartis/NIBR"
    }
  },

  "catalysts_2026": [
    {
      "event": "BROADEN2 Phase 2b AD enrollment completion",
      "timing": "2026",
      "program": "KT-621"
    },
    {
      "event": "KT-579 Phase 1 HV trial start",
      "timing": "Q1 2026",
      "program": "KT-579"
    },
    {
      "event": "KT-579 Phase 1 HV data",
      "timing": "2H 2026",
      "program": "KT-579"
    },
    {
      "event": "KT-485 Phase 1 start with Sanofi",
      "timing": "2026",
      "program": "KT-485"
    },
    {
      "event": "Advance CDK2 program with Gilead",
      "timing": "2026",
      "program": "CDK2"
    },
    {
      "event": "New IND for first-in-class oral immunology program",
      "timing": "2026",
      "program": "Research"
    }
  ],

  "catalysts_2027": [
    {
      "event": "BROADEN2 Phase 2b AD data",
      "timing": "Mid-2027",
      "program": "KT-621",
      "importance": "CRITICAL - key value driver"
    },
    {
      "event": "BREADTH Phase 2b Asthma data",
      "timing": "Late 2027",
      "program": "KT-621",
      "importance": "HIGH - validates respiratory"
    }
  ],

  "investment_analysis": {
    "bull_case": [
      "KT-621 Phase 1b data matches Dupixent - oral could transform $20B+ market",
      "KT-579 preclinical is best-in-class - 100% survival vs 67% vehicle in lupus",
      "Platform validated across STAT6, IRF5, IRAK4 - multiple shots on goal",
      "Strategic partnerships (Sanofi, Gilead) validate platform and provide funding",
      "Oral convenience could expand market penetration from 1-3% to 10%+",
      "Cash runway into 2029 - no near-term financing risk"
    ],
    
    "bear_case": [
      "KT-621 Phase 1b was open-label - need placebo-controlled data to confirm",
      "First-in-class transcription factor degraders - unknown unknowns",
      "KT-474 QTc issue raises questions (though KT-485 designed to address)",
      "Long development timelines - Phase 2b data not until 2027",
      "Competitive pressure from Dupixent ($13B franchise) and JAK inhibitors",
      "SLE (KT-579 target indication) is notoriously difficult"
    ],
    
    "key_debates": [
      {
        "question": "Can oral degraders truly match injectable biologics?",
        "bull_view": "Yes - 90%+ target degradation = complete pathway blockade",
        "bear_view": "No - tissue distribution and kinetics may differ",
        "what_resolves_it": "BROADEN2 EASI-75 at Week 16"
      },
      {
        "question": "Will the platform translate across targets?",
        "bull_view": "Yes - STAT6, IRF5, IRAK4 all showing translation",
        "bear_view": "Each target is different - past success doesn't guarantee future",
        "what_resolves_it": "KT-579 Phase 1 data, KT-485 Phase 1 data"
      }
    ],
    
    "valuation_framework": {
      "approach": "Sum-of-parts risk-adjusted NPV",
      "key_assumptions": {
        "kt621_ad_peak_sales": "$3-5B",
        "kt621_pos": "36%",
        "kt579_lupus_peak_sales": "$1-2B",
        "kt579_pos": "14%",
        "kt485_milestones_royalties": "$0.5B NPV"
      },
      "catalyst_sensitivity": {
        "broaden2_beat": "+50-100% stock impact",
        "broaden2_miss": "-40-60% stock impact"
      }
    }
  },

  "risks": [
    {
      "risk": "Clinical execution",
      "description": "Phase 2b trials may not replicate Phase 1b results",
      "mitigation": "Strong biomarker data supports efficacy; experienced team"
    },
    {
      "risk": "Safety signals",
      "description": "New target class may have unexpected toxicities",
      "mitigation": "Clean Phase 1 safety; genetic validation"
    },
    {
      "risk": "Competition",
      "description": "Dupixent franchise defended; other degrader companies emerging",
      "mitigation": "First-mover advantage; oral differentiation"
    },
    {
      "risk": "Regulatory",
      "description": "Novel mechanism may face heightened FDA scrutiny",
      "mitigation": "Standard development path; clear endpoints"
    }
  ],

  "sources": [
    {
      "title": "Kymera Therapeutics Corporate Presentation January 2026",
      "type": "Company Presentation",
      "date": "2026-01-15",
      "total_slides": 67,
      "key_sections": {
        "company_overview": "Slides 3-11",
        "kt621_deep_dive": "Slides 12-35",
        "kt579_deep_dive": "Slides 36-49",
        "partnered_programs": "Slides 50-52",
        "catalysts": "Slide 53",
        "appendix": "Slides 55-67"
      }
    }
  ]
}
